Amedisys INC Form 4 insider transactions

Amedisys Director Molly Joel Coye reported the disposition of all her shares following the company's acquisition by UnitedHealth Group for $101 per share.

Amedisys Director Julie D. Klapstein disposed of all her shares following the company's acquisition by UnitedHealth Group for $101 per share in cash.

Amedisys Director Paul B. K. Kusserow's equity and derivative holdings in Amedisys Inc. were converted or disposed of following the acquisition by UnitedHealth Group on August 14, 2025.

Amedisys Director Jeffrey A. Rideout reported the disposition of all his shares following the company's acquisition by UnitedHealth Group for $101 per share in cash.

Amedisys, Inc. director Vickie L. Capps reports disposition of shares following the company's acquisition by UnitedHealth Group for $101 per share in cash.

Amedisys Chief Legal Officer Jennifer G. Griffin's equity holdings converted to cash and UnitedHealth Group securities following the acquisition.

Amedisys's EVP, CFO & COO, Scott G. Ginn, reported significant changes in his beneficial ownership of company securities following the acquisition by UnitedHealth Group.

Amedisys Chief Compliance Officer's equity holdings converted to cash and UnitedHealth Group securities following the company's acquisition by UnitedHealth Group.

Amedisys Chief Accounting Officer Allyson Guidroz reports changes in her equity holdings following the company's acquisition by UnitedHealth Group on August 14, 2025.

AMEDISYS Inc.'s Chief Accounting Officer, Allyson Guidroz, was awarded 2,015 time-based Restricted Stock Units vesting over two years.

Amedisys's Chief Accounting Officer, Allyson Guidroz, disposed of 25 shares of common stock to cover tax withholding obligations related to equity compensation.

AMEDISYS Chief Strategy Officer Nick Muscato reported the disposition of 31 shares of common stock at $97.94 per share for tax purposes.

AMEDISYS Director Bruce D. Perkins reported a disposition of 105 shares of common stock via gift, reducing his direct beneficial ownership to 23,992 shares.

Amedisys Inc.'s Chief Accounting Officer, Allyson Guidroz, reported the disposition of 461 shares of common stock at $96.38 per share on July 1, 2025, primarily to cover tax liabilities.

AMEDISYS EVP, CFO & COO Scott Ginn reported the disposition of 2,327 shares of common stock at $98.03 per share to cover tax withholding obligations.

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., reported a disposition of 171 shares of common stock at $94.07 per share, primarily for tax withholding purposes, as detailed in a recent SEC Form 4 filing.

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., reports the sale of 374 shares of common stock at $96 per share on May 8, 2025.

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., disposed of 273 shares of common stock on May 3, 2025, to cover tax obligations.

Director Paul B. K. Kusserow reports changes in beneficial ownership of Amedisys Inc. stock, including acquisitions through a trust and 401(k) plan.

Director Teresa L. Kline received 1,690 restricted stock units from Amedisys Inc. on May 3, 2025, which will vest on May 3, 2026, contingent upon continued service on the Board of Directors.

Director Vickie L Capps of Amedisys Inc. was awarded 1,690 restricted stock units (RSUs) on May 3, 2025, which will vest on May 3, 2026, contingent upon continued service on the Board of Directors.

Director Ivanetta Davis Samuels receives 1,690 restricted stock units from Amedisys Inc.

Director Molly Joel Coye receives 1,690 restricted stock units from Amedisys Inc. vesting on May 3, 2026.

Director Jeffrey A. Rideout receives 1,690 restricted stock units from Amedisys Inc.

Director Julie D. Klapstein of Amedisys Inc. was awarded 1,690 restricted stock units on May 3, 2025, which will vest on May 3, 2026, contingent upon continued service on the Board of Directors.

Director Bruce D. Perkins acquired 1,690 restricted stock units in Amedisys Inc., vesting in May 2026.

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., sold 2,041 shares of common stock at an average price of $92.03 on March 4, 2025.

Denise M. Bohnert, Chief Compliance Officer of Amedisys Inc., reports changes in beneficial ownership of company stock due to tax withholding on vested shares and holdings in a 401(k) plan.

Scott Ginn, EVP, CFO & COO of Amedisys Inc., reports the disposal of 2,430 shares of common stock to cover tax obligations.

Nick Muscato, Chief Strategy Officer of Amedisys Inc., reports the disposition of shares to cover tax obligations related to vested stock.